Disarm Therapeutics has appointed Alvin Shih to serve as its president and CEO. He was most recently CEO of rare disease drug developer Enzyvant. Shih’s experience also includes posts at Retrophin (NASDAQ: [[ticker:RTRX]]) and Pfizer (NYSE: [[ticker:PFE]]). Cambridge, MA-based Disarm is developing drugs that target SARM1, a protein that plays a role in nerve deterioration in some neurodegenerative disorders.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
